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Abstract
Background: The purpose of this study is to evaluate and report the feasibility, safety, and initial outcomes of
patients with limited localized prostate cancer treated using a trans-rectal magnetic resonance image-guided
focused ultrasound (MRGFUS) device. Attempts to focally treat only the index lesion for prostate cancer have been
explored to reduce side effects while maintaining oncologic control. MRGFUS allows for precise targeting of
thermal ablative therapy with real-time thermometry.
Methods: Three patients underwent multiparametric 3T MRI and TRUS-guided 16-sector mapping biopsies of the
prostate. The patients were eligible if they had Gleason 6 or 7 (3 + 4) disease, no MRI-visible tumor ≥15 mm, no
extracapsular extension, and no more than two discrete cancerous lesions ≤10 mm in length. Acoustic power was
adjusted to achieve temperatures of 65 to 85 °C.
Results: Age ranged from 60 to 64 years. The number of biopsy-positive sectors treated ranged from 2 to 4. Post
therapy, 16-sector biopsies at 6 months were negative in two patients with one patient still with Gleason 6 cancer
(10 %, 2 mm) in one core. 16-sector biopsy in the first patient remains negative at 24 months. PSA continues to
remain stable in all patients. IPSS in all patients either remained stable or decreased then stabilized. Erectile function
according to the International Index of Erectile Function (IIEF) was excellent for all patients and demonstrated no
decline up to the time of last follow-up at 12–24 months.
Conclusions: MRGFUS is a feasible alternative for focal therapy in a select subset of patients with prostate cancer.
The treatment is well tolerated with no evidence of decline in functional outcomes. Initial post-therapy biopsy
results are promising. Long-term treatment efficacy requires further study.
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Background
Prostate cancer is the most common non-cutaneous ma-
lignancy diagnosed in men. As more than 60 % of these
cancers are considered multifocal, the standard of care
treatment for localized disease is whole gland therapy [1].
Unfortunately, the most common of these treatments,
surgery or radiation therapy, can be associated with long-
term functional side effects [2]. Recently, attempts to treat
the index lesion as part of a focal therapy strategy have
been explored to reduce side effects while maintaining ad-
equate oncologic control. Treatment modalities that have
been evaluated include cryotherapy, laser therapy, high-
intensity focused ultrasound (HIFU), photodynamic ther-
apy, and brachytherapy.
The experience with HIFU for focal therapy has been
limited and has primarily utilized ultrasound imaging to
target therapy. Marien et al. reviewed the published focal
therapy experience using HIFU which consisted of six
studies and a total of 133 patients [3]. Urinary retention
and dysuria ranged from 10 to 28 %, erectile dysfunction
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from 20 to 50 %, and urinary incontinence from 0 to
10 %. Biopsy-proven recurrence rates varied from 1 to
20 % for the entire prostate gland and 1 to 10 % for the
treated lobe. Ahmed et al. recently updated their experi-
ence and reported on 56 men with multifocal localized
prostate cancer treated to the index lesion using HIFU
[4]. The pad-free and leak-free continence rate was 92.3 %,
and erections sufficient for intercourse were preserved in
76.9 %. Histopathologic absence of clinically significant
cancer on the treated side was observed in 84.6 % and for
the entire gland 80.8 %. Finally, Cordeiro Feijoo et al. re-
ported on 67 men who underwent HIFU hemiablation [5].
Negative biopsies of the treated lobe were achieved in
83.6 % of the patients.
Multiparametric magnetic resonance imaging (MRI) has
become more prevalent in the staging and targeted biopsy
of prostate cancer. Recently, magnetic resonance image-
guided focused ultrasound (MRGFUS) has combined MRI
imaging and HIFU to allow for precise tumor targeting
and thermometry with real-time temperature feedback
within the gland during treatment. Napoli et al. showed
that in patients treated with MRGFUS followed by radical
prostatectomy, the prostate specimen demonstrated ac-
curate coagulative necrosis in the treatment zone indica-
tive of good energy delivery [6]. Lindner et al. previously
reported on one case using MRGFUS though oncologic
outcome was not examined [7]. This experience was re-
cently updated by Ghai et al. [8]. Four patients with cT1c–
T2a Gleason 6 very low risk and low risk disease were
treated. Three were biopsy negative post therapy, repre-
senting complete ablation of five of the six target lesions.
All patients had at least one Gleason 6-positive core
outside the treated zone. Quality of life scores were un-
changed 3 months after therapy. Herein, we report the
feasibility, safety, and initial post-therapy outcomes of the
first three patients with prostate cancer treated in the
USA using a trans-rectal MRGFUS device.
Methods
From November 2013 to July 2014, three men (ages
60–64) met eligibility criteria and received MRGFUS
focal therapy for prostate cancer as part of an Institu-
tional Review Board (IRB)-approved trial sponsored by
Insightec, Inc. (Haifa, Israel). Inclusion criteria included
(1) age between 55 and 75 years, (2) PSA <10, (3) Gleason
score ≤7 (3 + 4), (4) cT1c and cT2a, (5) maximum of two
lesions on most recent mapping biopsy with each cancer
site <10 mm in length, (6) prostate gland size <60 ml, (7)
no prior TURP, and (8) PSA density <0.15. Patients treated
with medications that could affect PSA value were eligible
if therapies were discontinued at least 3 months prior to
study entry.
All men underwent imaging with multiparametric 3T
MRI (GE Signa HDxt) without endorectal coil and CT
(GE Optima 560 PET-CT) and completed functional as-
sessment of urinary symptoms and erectile function using
validated questionnaires (International Prostate Symptom
Score (IPSS) and International Index of Erectile Function
(IIEF)). MRI parameters are presented in Table 1. Patients
were eligible for therapy if any MRI-visible tumor mea-
sured <15 mm, if no extracapsular extension was demon-
strated, and if no calcifications were identified on CT that
would be in the beam’s path. A trans-rectal ultrasound
(TRUS)-guided mapping biopsy of the prostate was then
Table 1 MRI parameters
Pulse sequence name Axial T1 FSE Axial/sag/coronal T2 FRFSE Axial DWI echo
planar imaging
(EPI)
Axial DCE GRE/FSPGR Pre-DCE T1 maps
Plane(s) of acquisition Obl/Axial oAx oSag oCor oAx Ax Ax Ax Ax
TR (msec) 750 2520 3050 2830 4275 2.5 2.5 2.5 2.5
TE (msec) 7.0 117 102 102 80 0.8 0.8 0.8 0.8
Flip angle 90 90 90 90 90 12 15 10 5
Matrix (cm) 256/192 320/256 320/256 320/256 128/128 160/160 160/160 160/160 160/160
Field of view (cm) 38/30 22/22 18/18 18/18 38/38 22/22 22/22 22/22 22/22
Slice thickness and slice gap (mm) 5.0/1.0 3.0/0.5 3.0/0.5 3.0/0.5 3.0/0.5 5.0/0.0 5.0/0.0 5.0/0.0 5.0/0.0
Number of signal averages 3 4 3 3 2 3 3 1.1 2.0 2.0 2.0
Parallel imaging factor TETRA/asset
Presence of fat suppression None None None None Yes None None None None
3 B values (s/mm2) None None None None 100 800 1400 None None None None
Vendor: GE 3T HDxt 16.0. Field strength 3 T. Type of coil (number of channels): HD TORSO ARRAY 8 CH. No endorectal coil. For DCE: concentration of gadolinium
(use 0.1 mmol/kg) MultiHance (gadobenate dimeglumine); rate of power injection 3 ml/s/volume based on weight of patient; volume of saline flush 3 ml/s/20 ml
saline flush; injection and scan delay: imaging begins/acquired immediately. After 22 s of imaging, gadolinium is injected (22-s contrast injection scan delay); time
per phase 8 s per phase/total scan time 04:33; number of phases 35
EPI echo planar imaging, FRFSE fast-relaxation fast spin echo, FSE fast spin echo, GRE gradient echo, DCE dynamic contrast exam, FSPGR fast spoiled gradient echo,
DWI diffusion-weighted imaging
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performed by the urologist of the treatment team (BY)
similar to a brachytherapy template with core biopsies of
16 sectors (Fig. 1). Patients were eligible for therapy if no
more than two discrete cancerous lesions were identified,
if ≤4 sectors were positive for cancer (i.e., two for each
cancerous lesion), if the total length of cancer focus was
<10 mm, and if each positive core was <7 mm in length.
Three men met all eligibility criteria and received
MRGFUS therapy 1 month after biopsy. All treatments
were administered using the ExAblate 2100 MRGFUS
system (Insightec Inc, Haifa, Israel) (Fig. 2) and were
performed as an outpatient under general anesthesia by
the same treatment team in a dedicated MRI suite in the
Department of Radiation Oncology. Prior to the day of
the procedure, the patient’s MRI and CT scans were
loaded into an Eclipse radiation oncology treatment
planning system (Varian, Inc., Palo Alto, CA). The pros-
tate gland was contoured, and results from the 16-sector
mapping biopsy were used to contour the sectors of the
gland to be treated. Normal organ avoidance structures
(neurovascular bundles, urethra, bladder wall, and rectal
wall) were also contoured.
Patients were placed on a low-residue diet 48 h prior, a
standard colonoscopy prep procedure started the day
prior, and a cleansing enema was administered 2 h prior
to the procedure. In the morning of the procedure, a QA
sonication was performed on a phantom gel to verify the
geometrical accuracy of treatment delivery. The patient
was then brought into the treatment suite, general
anesthesia was induced, a Foley catheter was placed, and
the patient was transferred to the ExAblate 2100 system
table and positioned supine in a knee-bent position. The
ExAblate 2100 trans-rectal FUS transducer was then
Fig. 1 Biopsy mapping template. Biopsy sectors were designated as follows: right anterior lateral apical (Ia); right anterior medial apical (IIa); right
posterior lateral apical (IIIa); right posterior medial apical (IVa); left anterior lateral apical (Va); left anterior medial apical (VIa); left posterior lateral apical
(VIIa); left posterior medial apical (VIIIa); right anterior lateral base (Ib); right anterior medial base (IIb); right posterior lateral base (IIIb); right posterior
medial base (IVb); left anterior lateral base (Vb); left anterior medial base (VIb); left posterior lateral base (VIIb); left posterior medial base (VIIIb)
Fig. 2 ExAblate 2100 treatment table docked to the MRI scanner
(top). Trans-rectal ultrasound transducer used to deliver therapy
(bottom) which consists of a 990-element phased array transducer
covered by an endorectal balloon containing circulating chilled
(14 °C degassed water)
Yuh et al. Journal of Therapeutic Ultrasound  (2016) 4:8 Page 3 of 7
carefully positioned in the rectum, and the patient moved
into the 3T MRI scanner (GE HDX). An endorectal bal-
loon covered the FUS transducer and was constantly filled
with circulating chilled degassed water to cool the rectal
wall during treatment delivery. T2-weighted images veri-
fied appropriate positioning of the transducer relative to
the prostate gland. T1-weighted images confirmed acous-
tic coupling of the endorectal balloon with the rectal wall.
The prostate gland, sectors to be treated, neurovascular
bundles, urethra, anterior rectal wall, and bladder wall
were then identified and contoured on each axial MRI
image. As per protocol, since none of the biopsy-positive
regions were visible on MRI, therapy was directed to the
regions or sectors which were biopsy positive as defined
by the biopsy template (Fig. 1). The ExAblate 2100 system
then determined the number of sonications needed to
treat and the proposed beam paths on each axial slice.
With each sonication, the treating physician first reviewed
and approved the proposed beam path and acoustic en-
ergy to deliver. MRI thermometry after each sonication
verified that the actual temperature approximated what
was predicted per treatment plan. Acoustic power was ad-
justed to achieve temperatures in the range of 65 to 85 °C.
At the completion of the treatment procedure, a final MRI
scan was performed and T2-weighted and T1 contrast-
enhanced sequences obtained to determine the volume of
non-perfused prostate gland volume that was present as a
result of therapy. Patients were then transported to a post-
surgical recovery area, the Foley discontinued, and the pa-
tient discharged home on antibiotics and an alpha-blocker
per standard institutional post prostate permanent seed
brachytherapy protocol.
Pain was measured on a 10-point numeric scale post-
operatively. Follow-up of patients post therapy included
assessment per protocol at 1 week and 1, 3, 6, 9, 12, and
18 months, with repeat 16-sector mapping biopsies at
6 months. Questionnaires were completed in person
during follow-up visits. IIEF-15 scores for the erectile
dysfunction domain (questions 1–5, 15) as well as total
questionnaire scores were tabulated.
Results
Baseline demographic and treatment characteristics of
the three patients treated are listed in Table 2. Age
ranged from 60 to 64 years. No cancers were visible by
CT or MRI, and prostate volume ranged from 21 to
51 ml. Two patients had no prior therapy. Patient 3 re-
ceived a 3-month injection of leuprolide 9 months prior
to therapy. The number of sectors which were biopsy
positive and treated ranged from 2 to 4. Patient 1 had
bilateral disease.
Treatment time for patient 1 was 3 h 55 min and sig-
nificantly longer than for patients 2 and 3. This was
due to an ExAblate system hardware fault which was
Table 2 Patient pre-therapy characteristics and treatment details
Patient 1 Patient 2 Patient 3
Age 64 60 61
BMI 26.5 25.4 23.9
Prostate volume (ml) 45.6 51 21
Gleason score 3 + 3 3 + 3 3 + 3
Clinical stage T1c T1c T1c
Pre-therapy PSA (ng/ml) 1.96 4.13 2.14
Previous therapy None None Leuprolide 3-month duration




No visible lesion No visible lesion No visible lesion
Sectors positive on biopsy pre-
therapy (% and length of core)
Right posterior lateral base
(2 %, 0.2 mm)
Left lateral base (5 %, 0.5 mm)
Left anterior lateral apex
(1 %, 0.2 mm)Left anterior medial
apex (1 %, 0.5 mm)
Left posterior lateral apex
(10 %, 5 mm)
Left anterior medial apex
(10 %, 2 mm)
Left posterior lateral apex
(5 %, 1 mm)
Left posterior medial apex
(20 %, 2.5 mm)
Left posterior medial base
(10 %, 2 mm)
Number of treatment (macro)
sonications
11 6 12
Total sonication time 3 h 55 min 1 h 3 min 1 h 46 min
Total time in scanner 6 h 18 min 3 h 34 min 3 h 40 min
Pain score postoperatively 0–1 0–1 0–1
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corrected after approximately 30 min and to movement
of the patient midway through the session requiring re-
positioning. Subsequent patients were treated with the
addition of paralytics to general anesthesia with treat-
ment times reduced to less than 2 h. The total number
of treatment macro-sonications ranged from 6 to 12.
Immediately after the final treatment sonication, all pa-
tients underwent a post-therapy MRI scan with and
without contrast while still in the treatment position to
correlate areas of non-perfusion within the gland with
areas which were intended to be treated. Figure 3
demonstrates the area of non-perfusion post therapy in
patient 3. No patient demonstrated intra-prostatic
hemorrhage on post-therapy MRI imaging. All men tol-
erated the procedure well and were discharged home
the same day. The Foley catheter remained in place
4 days for the first patient due to Foley trauma causing
hematuria prior to the start of therapy but was removed
in subsequent patients on the day of treatment. No
other complications were observed. At no time point
after treatment did pain scores exceed 1 in any patient.
Follow-up data are described in Table 3. Follow-up
ranged from 8 to 24 months. For patient 1, PSA de-
creased from 1.96 to 1.10 ng/ml by 3 months and has
remained stable up to 18 months. Patient 2 demon-
strated a rise in PSA to as high as 13.32 ng/ml at
5 months and with a return to baseline by 8 months,
probably representing the effects of inflammation of the
prostate after therapy. PSA has been stable in patient 3
out to 12 months. Sixteen-sector mapping biopsies per-
formed 6 months after therapy were negative for cancer
in two patients with one patient (patient 3) having Glea-
son 6 cancer (10 %, 2 mm) in one core from the left pos-
terior medial base. No patients developed urinary
incontinence. Pre-treatment IPSS scores ranged from 2
to 20; however, scores in all patients either remained
stable or decreased then stabilized. Pre-treatment erect-
ile function according to IIEF was excellent for all pa-
tients and demonstrated no decline up to time of last
follow-up.
Discussion
The present case series supports the findings of the ini-
tial experience that MRGFUS is safe and feasible for use
in focal therapy of prostate cancer in humans [7, 8]. In
three patients, treatment appeared to be well tolerated
with minimal procedural side effects or detrimental ef-
fect to urinary or erectile function. Early biopsy data at
6 months showed reduction or no residual tumor in all
patients. Biopsies remained negative at 24 months in the
first patient.
Fig. 3 Post contrast T1-weighted axial image immediately after the
completion of therapy in patient 3 with Gleason 6 disease in the
left anterior medial apex, left posterior lateral apex, left posterior
medial apex, and left posterior medial base. The treatment area
demonstrates non-perfusion of tissue after MRGFUS thermal abla-
tion. NV neurovascular bundle
Table 3 Follow-up data including PSA, biopsy results, and
functional outcome
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30 (75) 29 (66) 30 (69)
3 months post
therapy
30 (73) 30 (73) 29 (65)
6 months post
therapy
30 (73) 28 (66) 30 (66)
9 months post
therapy
29 (74) 30 (71) 30 (68)
12 months post
therapy
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The rationale behind focal therapy continues to be
debated, and little evidence exists with respect to its
long-term efficacy. For focal therapy to be an accept-
able alternative, it is essential that the side effect profile
be significantly improved compared to whole gland treat-
ment. In a recent systematic review of focal therapy, re-
ported continence ranged from 95 to 100 % and erectile
function ranged from 54 to 100 % [9]. In an ideal state,
focal therapy would provide oncologic results approaching
those of the standard of care treatment with a reduction
in side effects, while also providing an intervention option
to mitigate anxiety related to active surveillance.
Questions remain as to which patients are best suited
for focal ablative therapy. Active surveillance has assumed
a prominent role in the management of indolent tumors,
or those cancers that are unlikely to progress. However,
some men choose active treatment even with lower risk
disease due to anxiety, fear of progression, or concern
about prostate cancer-related death [10]. For men diag-
nosed with early stage, lower risk, well-circumscribed
cancers, an effective, less invasive treatment is compelling.
Selection of the best candidates for focal therapy is a crit-
ical decision point. Bulky, large-volume, multifocal tumors
are challenging for this technology to cover the entire
targeted area or treat multiple locations which may in turn
increase the need for further local treatment. Thus, pa-
tients best suited for a focal therapy procedure are those
with low-risk, low-volume disease that are likely to pro-
gress or intermediate-risk disease diagnosed at a confined
early stage. Questions also remain as to how much of the
gland to treat, hemiablation of one lobe, or targeted abla-
tion of just the index lesion.
Recently, an international consensus panel published
guidelines on trial design for focal therapy of localized
prostate cancer [11]. Ablation templates defined were tar-
geted ablation (single target), zonal ablation, or hemiabla-
tion. Suggested inclusion criteria were Gleason 7 (3 + 4)
and clinically significant Gleason 6 disease, clinical stage
T1c–T2a, PSA <15 ng/ml, and life expectancy >10 years,
and for patients receiving HIFU, a gland size ≤40 ml. The
primary endpoint should be focal ablation of clinically sig-
nificant disease, defined as prostates with a dominant
tumor >0.5 ml, with negative biopsies at 12 months after
treatment.
Although different treatment modalities have been
evaluated for focal therapy, the modality that best opti-
mizes cancer control and limits side effects remains
unknown. MRGFUS offers several potential benefits.
High-resolution MRI for prostate imaging has shown
an ability to enhance anatomic evaluation and detect
significant tumors and higher grade tumors. More fre-
quently, MRI is used in active surveillance programs as an
adjunctive tool to evaluate for undiagnosed lesions of
higher grade or progression of disease. In the setting of
radiographic-visible disease or with 3-dimensional map-
ping of a non-visible tumor, MRI already plays a vital role
in focal therapy planning and treatment. Using the same
platform for diagnosis (targeted biopsy), targeted treat-
ment (MRGFUS), and follow-up biopsy (registered tar-
geted biopsy) is efficient [12]. The melding of MRI and
HIFU provides excellent visualization of patient anatomy,
precise tumor targeting, and controlled treatment con-
tinuously monitoring the tissue effect with temperature
feedback.
In a study of 42 men treated with focal standard HIFU,
treatment was associated with decreases in IIEF-15 erect-
ile function and orgasmic domains though overall IIEF-15
scores were stable and IPSS scores showed an improve-
ment in lower urinary tract symptoms. Seventy-seven per-
cent of the men had no evidence of cancer on 6-month
biopsy [13]. In another study of 106 men treated with a
variety of focal therapy modalities, 13 % experienced com-
plications related to treatment with 2 % experiencing
complications of Clavien grade 3 [14].
In the present study, a zonal ablation approach was
utilized where all biopsy-positive sectors were treated.
Initial results are encouraging. Functional outcome was
maintained and early biopsy results were suggestive of
sufficient local treatment. No patients experienced a
decrement in erectile function or urinary function.
Prostate biopsies at 6 months post therapy were nega-
tive in two of the three patients. In patient 3, three of
the four sectors treated converted to biopsy negative
and the left posterior medial base sector demonstrated
a clinically insignificant amount of remaining Gleason 6
cancer (2 mm). This patient is currently being followed
off therapy with plans to perform a biopsy at 24 months
per protocol. Factors in patient 3 that may have contrib-
uted to persistent disease on 6-month biopsy include
greater tumor burden, prior androgen deprivation therapy
which may have resulted in an underestimate of tumor
burden and multifocality on mapping biopsies, and mar-
ginal treatment of that sector in an attempt to avoid the
adjacent urethra.
The limitations of this study to date include a small
sample size and limited follow-up. The efficacy of the
procedure could be limited by targeting accuracy,
learning curve, or multifocality of cancer. PSA kinetics
after MRGFUS are undetermined as it relates to treat-
ment success. While the treatment time could be con-
sidered prolonged for focal treatment, the length of
procedure is expected to decrease with improved tech-
nical experience.
Conclusions
MR-guided focused ultrasound is a feasible alternative for
focal therapy in a select subset of patients with prostate
cancer. The treatment appears to be well tolerated with
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no evidence of decline in early functional outcomes. The
effect on urinary control, erectile function, pain, and mor-
bidity was minimal. While early results from a biopsy
standpoint appear promising, long-term treatment efficacy
requires further study.
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